Mumbai: Pfizer Inc, the world`s largest drugmaker, has scrapped a deal to sell insulin products made by Biocon Ltd, leaving India`s biggest biotechnology company without a partner to sell the drugs in key markets such as the United States.Pfizer cited other priorities in its biosimilar program for the split, which immediately ends a relationship that stood to earn Biocon hundreds of millions of dollars in royalties. Shares of Biocon fell 6.3 percent.
Will write my own book to tell the truth: Sonia
India-US ties at turning point: Sushma Swaraj
Hrithik upset with Rs 400 cr alimony rumours
Eating chicken could make you immune to antibiotics